Nusinersen

Not Applicable

04/06/2024 Nusinersen and risdiplam for treating spinal muscular atrophy

The Ministry of Health’s Drug Advisory Committee has recommended:

• Risdiplam 0.75 mg/mL powder for oral solution for treating:

  • Symptomatic Type 1, 2 or 3 spinal muscular atrophy (SMA) in patients who are/were 18 years of age or under at the time of initial treatment with risdiplam or nusinersen;

  • Symptomatic Type 1, 2 or 3 SMA in patients aged 19 years or above who had not initiated treatment with risdiplam or nusinersen prior to 19 years of age despite onset of signs/symptoms of SMA;

  • Pre-symptomatic SMA in patients who are/were under 3 years of age at the time of initial treatment with risdiplam or nusinersen; and

  • SMA in patients who have experienced a regression in a developmental state despite treatment with gene therapy.

Funding status

[R] Risdiplam 0.75 mg/mL powder for oral solution is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 August 2024.

[R] Risdiplam should be used in line with the additional clinical criteria listed in the Annex.

[NR] MAF assistance does not apply to nusinersen for treating SMA.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.